The demo achieved both equally its primary endpoints, with semaglutide 2.four mg demonstrating statistically considerable and outstanding enhancements in liver fibrosis without worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in people with MASH as compared to placebo.oneExcretion The first ex… Read More